Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule with the molecular formula C23H16N2O5 and a molecular weight of approximately 400.39 g/mol. This compound is a member of the pyrrolo[3,4-c]carbazole family and features a propanoic acid side chain at the N6 position of the core scaffold. It was developed as part of research into inhibitors targeting cell cycle checkpoint kinases—specifically Wee1 and Chk1—which are important regulators in cancer cell division. Acidic N6 side chains on this scaffold confer potent (average IC50 ~0.057 μM) and selective (average ratio ~223-fold over Chk1) inhibition of Wee1 kinase activity by binding to its ATP-binding site; co-crystal structures confirm this interaction with key hydrogen bonding to conserved water molecules in the active site. In cellular assays (e.g., HT29 cells treated with doxorubicin followed by this compound), it abrogates G2/M checkpoint arrest by inhibiting phosphorylation events required for cell cycle progression control—demonstrating potential as an antineoplastic agent through checkpoint kinase inhibition[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(9-hydroxy-1,3-dioxo-4-phenyl-2,3-dihydropyrrolo[3,4-c]carbazol-6(1H)-yl)propanoic acid.